Regulation of iron regulatory protein 1 during hypoxia and hypoxia/reoxygenation.
Given the important relationship between O2 and iron (Fenton chemistry) a study was undertaken to characterize the effects of hypoxia, as well as subsequent reoxygenation, on the iron-regulatory proteins 1 and 2 (IRP1 and IRP2) in a rat hepatoma cell line. IRP1 and IRP2 are cytosolic RNA-binding proteins that bind RNA stem-loops located in the 5'- or 3'-untranslated regions of specific mRNAs encoding proteins that are involved in iron homeostasis. In cells exposed to hypoxia, IRP1 RNA binding was decreased approximately 2. 8-fold after a 6-h exposure to 3% O2. Hypoxic inactivation of IRP1 was abolished when cells were pretreated with the iron chelator desferrioxamine, indicating a role for iron in inactivation. IRP1 inactivation was reversible since re-exposure of hypoxically-treated cells to 21% O2 increased RNA binding activity approximately 7-fold after 21 h with an increase in activity seen as early as 1-h post-reoxygenation. IRP1 protein levels were unaffected during hypoxia as well as during reoxygenation. Whereas the protein synthesis inhibitor cycloheximide did not block IRP1 inactivation during hypoxia, it completely blocked IRP1 reactivation during subsequent reoxygenation. Reactivation of IRP1 during reoxygenation was also partially blocked by the phosphatase inhibitor okadaic acid. Finally, reactivated IRP1 was found to be resistant to inactivation by exogenous iron known to down-regulate its activity during normoxia. These data demonstrate that IRP1 RNA binding activity is post-translationally regulated during hypoxia and hypoxia/reoxygenation. Regulation of IRP1 by changing oxygen tension may provide a novel mechanism for post-transcriptionally regulating gene expression under these stresses.
Hanson
E S
ES
Eccles Program in Human Molecular Biology and Genetics and the Department of Medicine, University of Utah, Salt Lake City, Utah 84112, USA.
Leibold
E A
EA
D000818:Animals; D015687:Cell Hypoxia; D003513:Cycloheximide / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D035941:Iron Regulatory Protein 1; D035942:Iron Regulatory Protein 2; D035925:Iron-Regulatory Proteins; D007506:Iron-Sulfur Proteins / Q000378:metabolism*; D009206:Myocardium / Q000166:cytology / Q000378:metabolism; D019319:Okadaic Acid / Q000494:pharmacology; D010100:Oxygen / Q000378:metabolism*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012313:RNA / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism*; D051381:Rats; D014407:Tumor Cells, Cultured
D004791:Enzyme Inhibitors; D035925:Iron-Regulatory Proteins; D007506:Iron-Sulfur Proteins; D011500:Protein Synthesis Inhibitors; D016601:RNA-Binding Proteins; D019319:Okadaic Acid; D012313:RNA; D003513:Cycloheximide; D035941:Iron Regulatory Protein 1; D035942:Iron Regulatory Protein 2; D010100:Oxygen